Brief: Nanobiotix Establishes Recommended Dose For Planned Registrational Study Evaluating NBTXR3 Plus ANTI-PD-1

Nanobiotix SA

21/09/2022 22:22

Sept 21 (Reuters) - Nanobiotix SA  NANOB.PA :
    * NANOBIOTIX ESTABLISHES RECOMMENDED DOSE FOR PLANNED
REGISTRATIONAL STUDY EVALUATING NBTXR3 PLUS ANTI-PD-1 FOR
PATIENTS WITH METASTATIC HEAD AND NECK CANCER RESISTANT TO PRIOR
IMMUNOTHERAPY
    * NANOBIOTIX SA - RECOMMENDED PHASE 2 DOSE ESTABLISHED AT
33% OF
GROSS TUMOR VOLUME IN ALL THREE COHORTS FROM COMPLETE ESCALATION
PART OF STUDY 1100
    * NANOBIOTIX SA - UPDATED CLINICAL DATA FROM STUDY 1100
EXPECTED
IN Q4 2022
    * NANOBIOTIX - SUBMISSION OF PROTOCOL TO FDA FOR PHASE 3
CLINICAL
TRIAL EVALUATING NBTXR3 WITH ANTI-PD-1 EXPECTED IN Q1 2023

Source text for Eikon:  ID:nBw1NdBxJa 
Further company coverage:  NANOB.PA 

 ((Reuters.Briefs@thomsonreuters.com;))